Impact of pathological complete response following neoadjuvant chemotherapy (gemcitabine, nab-paclitaxel, S-1) and radiation for borderline resectable pancreatic cancer: a case report and review of literature

Impact of pathological complete response following neoadjuvant chemotherapy (gemcitabine, nab-paclitaxel, S-1) and radiation for borderline resectable pancreatic cancer: a case report and review of literature

Abstract Background Pancreatic cancer (PC) is a highly lethal malignancy, even if surgical resection is possible (median survival: < 30 months). The prognosis of borderline resectable pancreatic cancer (BR-PC) is even worse. There is no clear consensus on the optimal treatment strategy, including...

Full description

Saved in:
Bibliographic Details
Main Authors: Mitsuru Kinoshita, Sota Watanabe, Gaku Mizojiri, Akitada Sada, Hiroki Kai, Yasunori Masuike, Yoshinobu Nagasawa, Kentaro Maruyama, Kyowon Lee, Mai Ohata, Osamu Ishikawa, Hiroshi Oka
Format: Article
Language:English
Published: Japan Surgical Society 2022-09-01
Series:Surgical Case Reports
Subjects:
Borderline resectable pancreatic cancer
Neoadjuvant chemoradiation therapy
Pathological complete response
Online Access:https://doi.org/10.1186/s40792-022-01529-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items